Human-Derived Organ-on-a-Chip for Personalized Drug Development

Area of Science:

• Biomedical Engineering
• Pharmacology
• Stem Cell Biology

Background:

• High attrition rates (>90%) in clinical drug development underscore the need for predictive preclinical models.
• Current models (computational, cell culture, animal) have limitations in predicting human drug response.
• Organ-on-a-chip (OOC) technology offers a promising alternative for robust drug screening.

Purpose of the Study:

• To review advances in OOC platforms for pharmaceutical drug testing.
• To highlight the integration of human-induced pluripotent stem cells (hiPSCs) in OOC models.
• To discuss the potential of OOCs in predicting drug efficacy and safety, and their role in clinical trials.

Main Methods:

• Review of recent literature on OOC platforms and hiPSC-based organoid development.
• Analysis of studies integrating multiple organs on a chip to model ADMET processes.
• Examination of OOC applications in preclinical and clinical drug discovery stages.

Main Results:

• OOC platforms demonstrate flexibility and robustness in drug screening.
• hiPSC-derived personalized tissue/organ models are increasingly utilized.
• Multi-organ OOC systems enhance the prediction of drug absorption, distribution, metabolism, excretion, and toxicity (ADMET).

Conclusions:

• OOCs, particularly those using hiPSCs, show significant potential to improve drug efficacy and safety predictions.
• These platforms can reduce capital and time investment in drug development.
• Further research and integration into clinical trials are crucial to overcome remaining challenges.